[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472797":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":36,"responsibleParty":69,"collaborators":30,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":30,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":30,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":30,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MBF-RIC","EXPERIMENTAL","Patients with MBF-RIC as conditioning regimen",[13],"Drug: MBF-RIC",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan",[9],[20],"MBF100",[22],{"name":23,"affiliation":5,"role":24},"Jiong Hu","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Jieling Jiang","CONTACT","+8613311986505",null,"jiangjieling66@hotmail.com",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"jiong HU","+8613764313546","hj10709@rjh.com.cn",[37,59],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Blood & Marrow Transplantation Center, RuiJin Hospital","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":46,"coordinates":47},"Point",[48,49],121.45806,31.22222,{"lat":49,"lon":48},[52,56],{"name":53,"role":28,"phone":54,"phoneExt":30,"email":55},"Jiong HU, M.D.,","86-21-64370045","hujiong@medmail.com.cn",{"name":57,"role":28,"phone":54,"phoneExt":30,"email":58},"Ling Wang, M.D.,","cclingjar@163.com",{"facility":60,"status":39,"city":40,"state":30,"zip":30,"country":43,"countryCode":44,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Shanghai No 6 Hospital",{"type":46,"coordinates":62},[48,49],{"lat":49,"lon":48},[65],{"name":66,"role":28,"phone":67,"phoneExt":30,"email":68},"ChunKang Chang","+862164369181","changchunkang@sjtu.edu.cn",{"type":24,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Jiong HU","Head, Blood & Marrow Transplantation Center, Rui Jin Hospital","100472797","phase-2-reduced-mbf-regimen-for-patients-55-years-with-myeloid-malignancies-100472797",false,"NCT05436561","Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies","A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.","Inclusion Criteria:\n\n* Age 55-65\n* patients with HLA-matched sibling donors, 9-10\u002F10 matched unrelated donors or haplo-identical donors.\n* patients with AML in remission, or MDS in any stage, or CMML in any stage\n* inform consent provided\n\nExclusion Criteria:\n\n* patients with abnormal liver (\\>3N), renal (1.5N) or cardiac function\n* patients with active infection","ALL","55 Years","65 Years",{"count":83,"type":84},61,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg\u002Fm2), busulfan (6.4mg\u002Fkg) and melphalan (100mg\u002Fm2) in patients with myeloid malignancies including AML, MDS and CMML \\>=55 years.",[90],"Disease-free Survival","2026-03-15",{"date":93,"type":94},"2026-03-17","ACTUAL",{"date":96,"type":94},"2022-06-01",{"date":98,"type":84},"2027-06-30",{"name":5,"class":6},2]